We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.29%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.31B
AUM Growth
+$931M
Cap. Flow
+$3.42M
Cap. Flow %
0.05%
Top 10 Hldgs %
41.19%
Holding
233
New
22
Increased
88
Reduced
44
Closed
17

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$66M
2
CRL icon
Charles River Laboratories
CRL
+$38M
3
WVE icon
Wave Life Sciences
WVE
+$20.8M
4
ABT icon
Abbott
ABT
+$19M
5
PACB icon
Pacific Biosciences
PACB
+$17.1M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$108M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$84.7M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$53.2M
4
GILD icon
Gilead Sciences
GILD
+$35.4M
5
TDOC icon
Teladoc Health
TDOC
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.59%
2 Industrials 0.45%
3 Technology 0.42%
4 Communication Services 0.09%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHNG
76
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$14.2M 0.22%
863,922
– –
HOLX
77
DELISTED
Hologic
HOLX
$13.7M 0.22%
261,779
+106,571
+69% +$5.31M
SUPN icon
78
Supernus Pharmaceuticals
SUPN
$2.78B
$13.7M 0.22%
575,600
+159,000
+38% +$3.86M
COO icon
79
Cooper Companies
COO
$14B
$13.3M 0.21%
166,140
+38,264
+30% +$2.89M
NVRO
80
DELISTED
NEVRO CORP.
NVRO
$12.9M 0.2%
109,705
-35,406
-24% -$3.51M
MASI
81
DELISTED
Masimo
MASI
$12.5M 0.2%
79,049
+10,657
+16% +$1.6M
IDXX icon
82
Idexx Laboratories
IDXX
$44.4B
$12.4M 0.2%
47,461
+13,327
+39% +$3.51M
TNDM icon
83
Tandem Diabetes Care
TNDM
$1.22B
$11.9M 0.19%
200,147
+5,411
+3% +$334K
RMD icon
84
ResMed
RMD
$28.6B
$11.7M 0.19%
75,810
+21,180
+39% +$3.05M
GNMK
85
DELISTED
GenMark Diagnostics, Inc
GNMK
$11.7M 0.19%
2,441,241
+173,989
+8% +$960K
HZNP
86
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$11.4M 0.18%
315,700
-7,600
-2% -$233K
PEN icon
87
Penumbra
PEN
$12.5B
$11.3M 0.18%
68,855
+43,807
+175% +$6.97M
OXFD
88
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$10.6M 0.17%
637,972
– –
QTRX icon
89
Quanterix
QTRX
$187M
$10.3M 0.16%
435,217
+29,116
+7% +$664K
TXG icon
90
10x Genomics
TXG
$5.49B
$9.85M 0.16%
129,127
+29,127
+29% +$1.75M
TRHC
91
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$9.82M 0.16%
201,635
-58
-0% -$2.72K
AMGN icon
92
Amgen
AMGN
$197B
$9.73M 0.15%
40,350
-17,350
-30% -$3.82M
LIVN icon
93
LivaNova
LIVN
$4.37B
$9.55M 0.15%
126,639
-144,675
-53% -$11M
INGN icon
94
Inogen
INGN
$172M
$9.41M 0.15%
137,787
+24,464
+22% +$1.53M
XRAY icon
95
Dentsply Sirona
XRAY
$2.74B
$9.4M 0.15%
166,039
+34,221
+26% +$1.91M
IRTC icon
96
iRhythm Holdings
IRTC
$3.7B
$9.3M 0.15%
136,563
-47,856
-26% -$3.25M
SWAV
97
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$9.26M 0.15%
210,758
+109,400
+108% +$4.04M
AMED
98
DELISTED
Amedisys
AMED
$8.91M 0.14%
53,365
-122,293
-70% -$18.2M
CDTX
99
DELISTED
Cidara Therapeutics
CDTX
$8.81M 0.14%
114,764
– –
GH icon
100
Guardant Health
GH
$19.9B
$8.61M 0.14%
110,136
+15,375
+16% +$1.11M
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2019 Portfolio in Review

As of Q4 2019, Bellevue Group held 233 positions worth $6.31B, up 17% from $5.38B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q4 2019 filing shows 22 new, 88 increased, 44 reduced and 17 closed positions. Its largest new stake was Molecular Templates, Inc.: 86,379 shares worth $18.1M. The largest sale was Celgene Corp, an estimated $108M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q4 2019 buy was Molecular Templates, Inc.: 86,379 shares worth $18.1M.
  • Bellevue Group added most to Bristol-Myers Squibb in Q4 2019, an estimated $66M increase.
  • Bellevue Group's biggest Q4 2019 reduction was Audentes Therapeutics, Inc, cutting an estimated $53.2M.
  • Bellevue Group fully exited Celgene Corp in Q4 2019, selling an estimated $108M.
  • Bellevue Group's ten largest holdings make up 41% of its $6.31B portfolio in Q4 2019.
  • Bellevue Group opened 22 new positions and closed 17 in Q4 2019.
  • Bellevue Group's portfolio value rose 17% quarter-over-quarter to $6.31B.

Based on Bellevue Group's 13F filing for Q4 2019, filed 14 Feb 2020.